JPMorgan analyst Jessica Fye raised the firm’s price target on Alnylam (ALNY) to $348 from $338 and keeps an Overweight rating on the shares. The firm increased Amvuttra forecasts in transthyretin amyloid cardiomyopathy through 2029 ahead of the company’s Q2 report. It expects Alnylam’s TTR franchise guidance to move higher with the results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $312 from $287 at Morgan Stanley
- BridgeBio price target raised to $56 from $53 at Leerink
- Alnylam price target raised to $359 from $336 at BofA
- Alnylam price target raised to $404 from $364 at Citi
- Alnylam Pharma’s Promising Growth and Market Potential Justify Buy Rating